±î½ºÆÄÆÄ¾×
ÀϹÝÀǾàǰ | ºñ±Þ¿©
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
monogen ȸ¿ø´ÔÀÇ Ã¤ÅÃµÈ »çÁøÀÔ´Ï´Ù.
°¨¹Ìû·®°¨ ÇâÃë°¡ ÀÖ´Â ¹ÌȲ»öÀÇ ºñµî¼º¾×Á¦
Á¦Á¶È¸»ç
(ÁÖ)ÀÏÈ
ÆÇ¸Åȸ»ç
(ÁÖ)ÀÏÈ
Çã°¡Á¤º¸
ÃëÇÏ
(2019.07.30)
BIT ¾àÈ¿ºÐ·ù
À§Àå¿îµ¿Á¶Àý ¹× Áø°æÁ¦ (GI Tract Regulators & Antispasmodics)
º¹ÁöºÎºÐ·ù
239[±âŸÀÇ ¼Òȱâ°ü¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
640900110 [ºñ±Þ¿©]
ATCÄÚµå
Antispasmodics in combination with other drugs / A03ED
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¹é´ç ,
º¥Á¶»ê³ªÆ®·ý ,
½ÃÆ®¸£»ê¼öȹ° ,
¿¡Åº¿Ã ,
Á¤Á¦¼ö ,
Á¶ÇÕÇâ·á(¿À·»Áö¿¡¼¾½º) ,
Á¶ÇÕÇâ·á(Ä«½Ã¾ÆÈÄ·¹¹Ùµð-911053) ,
Á¶ÇÕÇâ·á(ÆäÆÄ¹ÎÆ®¿¡¼¾½º B-940620) ,
Æú¸®¼Ò¸£º£ÀÌÆ®80 ,
L-¸àÅç
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
640900110
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
°¨¹Ìû·®°¨ ÇâÃë°¡ ÀÖ´Â ¹ÌȲ»öÀÇ ºñµî¼º¾×Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
75¹Ð¸®¸®ÅÍ
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
Æ÷ÀåÇüÅÂ
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
75¹Ð¸®¸®ÅÍ
1 °³
º´
8806409001103
8806409001110
ÁÖ¼ººÐÄÚµå
A29800ALQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
À§Åë, º¹Åë , »êÅë, À§»ê°ú´Ù , ¼Ó¾²¸²
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ 1ȸ 1º´(75ml) 1ÀÏ 3ȸ ½ÄÈÄ¿¡ º¹¿ëÇÑ´Ù.
½ÅÁßÅõ¿©
1) ¾àÀ¸·Î ¾Ë·¹¸£±â Áõ»ó(¹ßÁø , ¹ßÀû, °¡·Á¿ò µî)À» ÀÏÀ¸Å² ÀÏÀÌ Àִ ȯÀÚ
2) ½ÉÀå¾Ö ȯÀÚ, ³ì³»Àå ¶Ç´Â ¹è´¢°ï¶õ ÀÌ Àִ ȯÀÚ, Çã¾àÀÚ ¶Ç´Â °í·ÉÀÚ
3) ÀӺΠ¶Ç´Â ÀӽŠÇϰí ÀÖÀ» °¡´É¼ºÀÌ Àִ ȯÀÚ
4) ´Ù¸¥ ¾à¹°À» Åõ¿© ¹Þ°í Àִ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ¾Ë·¹¸£±â Áõ»ó(¹ßÁø , °¡·Á¿ò µî)ÀÌ ³ªÅ¸³¯ ¶§¿¡´Â Åõ¿©¸¦ ÁßÁö Çϰí
¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
2) ÀÌ ¾àÀ» Åõ¿©ÇÔÀ¸·Î½á ±¸°¥, º¯ºñ ÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶Ç µÎÅë , ¾È¸éÈ«Á¶ , ´«ºÎ ½É, ¹è´¢°ï¶õ µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁö ÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
»óÈ£ÀÛ¿ë
½ºÄÚÆú¸®¾Æ¿¢½º ¸¦ ÇÔÀ¯ÇÏ´Â Á¦Á¦ ¹× ±âŸ À§ÀåÁøÅëÁø°æÁ¦¿Í º´¿ë Åõ¿©ÇÏÁö ¾Ê´Â´Ù .
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
(papaverine; )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Papaverine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.
Pharmacology
Papaverine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.
Metabolism
Papaverine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Xanthine dehydrogenase/oxidase
Protein Binding
Papaverine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ ~90%
Half-life
Papaverine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 0.5-2 hours
Absorption
Papaverine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Pharmacokinetics
Papaverine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÀÛ¿ë¹ßÇö½Ã°£ : °æ±¸ : ½Å¼Ó
´Ü¹é°áÇÕ : 90%
´ë»ç : °£¿¡¼ ½Å¼ÓÈ÷ ´ë»ç
¹Ý°¨±â : 0.5-1.5½Ã°£
¼Ò½Ç : ´¢¸¦ ÅëÇØ ÁÖ·Î ´ë»çü·Î ¹è¼³
Biotransformation
Papaverine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Toxicity
Papaverine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Drug Interactions
Papaverine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Papaverine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
Drug Target
[Drug Target]
Description
Papaverine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]
Drug Category
Papaverine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Phosphodiesterase InhibitorsVasodilator Agents
Smiles String Canonical
Papaverine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
Smiles String Isomeric
Papaverine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
InChI Identifier
Papaverine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
Chemical IUPAC Name
Papaverine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ